The antibody quantity administrated to the tumor-bearing mice was consulted to the clinical usage of Herceptin in treating patients with HER2-positive tumours, which was a humanized antibody specifically developed to target human epidermal growth factor receptor 2 (HER2) [32]. The gene discussed is ERBB2; the disease is neoplasm.